<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35094205</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1559-0283</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>80</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cell biochemistry and biophysics</Title>
          <ISOAbbreviation>Cell Biochem Biophys</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Itraconazole-Induced the Activation of Adenosine 5'-Monophosphate (Amp)-Activated Protein Kinase Inhibits Tumor Growth of Melanoma via Inhibiting ERK Signaling.</ArticleTitle>
        <Pagination>
          <StartPage>331</StartPage>
          <EndPage>340</EndPage>
          <MedlinePgn>331-340</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12013-021-01048-y</ELocationID>
        <Abstract>
          <AbstractText>Itraconazole, an effective broad-spectrum antifungal drug, has been well established for its anticancer activity in cancers including melanoma. However, details concerning its underlying mechanism in melanoma are unclear. This work investigated the function of itraconazole-induced 5'-monophosphate (AMP)-activated protein kinase alpha (AMPKα) in melanoma progression through ERK signaling. The AMPKα level in melanoma tissues and cells was assessed by RT-qPCR and western blot. Survival analysis of patients with melanoma based on the AMPKα expression level was performed according to TCGA database. Melanoma cell proliferation, migration, and invasion were examined using CCK-8, colony formation, wound healing, and Transwell assays. A xenograft tumor model was established to examine the effect of itraconazole on tumor growth in vivo. The AMPKα mRNA and protein levels were reduced in melanoma tissues and cells. A low expression of AMPKα indicated a poor prognosis. Functionally, itraconazole restrained melanoma cell proliferation, migration, and invasion by upregulating AMPKα. Itraconazole activated AMPK signaling and inhibited ERK signaling in melanoma cells. Activation of ERK signaling reversed the effect of itraconazole on cellular process in melanoma. Moreover, itraconazole-induced AMPKα inhibited melanoma tumor growth in vivo by inhibiting ERK signaling. Itraconazole-induced AMPKα inhibits the progression of melanoma by inhibition of ERK signaling.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Fan</LastName>
            <ForeName>Ni</ForeName>
            <Initials>N</Initials>
            <Identifier Source="ORCID">0000-0003-0733-5711</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, The Affiliated Zhangjiagang Hospital of Soochow University, Suzhou, 215600, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Yueping</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0001-7559-1253</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gynaecology and Obstetrics, The Affiliated Zhangjiagang Hospital of Soochow University, Suzhou, 215600, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yan</LastName>
            <ForeName>Lv</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0002-6393-7947</Identifier>
            <AffiliationInfo>
              <Affiliation>Center of Translational Medicine, The Affiliated Zhangjiagang Hospital of Soochow University, Suzhou, 215600, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Weining</ForeName>
            <Initials>W</Initials>
            <Identifier Source="ORCID">0000-0003-2759-9976</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, The Affiliated Zhangjiagang Hospital of Soochow University, Suzhou, 215600, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yueping</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0003-4490-4610</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, The Affiliated Zhangjiagang Hospital of Soochow University, Suzhou, 215600, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Shusheng</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0003-2621-4050</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, The Affiliated Zhangjiagang Hospital of Soochow University, Suzhou, 215600, Jiangsu, China. drwangsszjg@hotmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Song</LastName>
            <ForeName>Yu</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0003-1083-4263</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, The Affiliated Zhangjiagang Hospital of Soochow University, Suzhou, 215600, Jiangsu, China. sy5449@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cell Biochem Biophys</MedlineTA>
        <NlmUniqueID>9701934</NlmUniqueID>
        <ISSNLinking>1085-9195</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>304NUG5GF4</RegistryNumber>
          <NameOfSubstance UI="D017964">Itraconazole</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>415SHH325A</RegistryNumber>
          <NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.31</RegistryNumber>
          <NameOfSubstance UI="D055372">AMP-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>K72T3FS567</RegistryNumber>
          <NameOfSubstance UI="D000241">Adenosine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D055372" MajorTopicYN="N">AMP-Activated Protein Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000241" MajorTopicYN="N">Adenosine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000249" MajorTopicYN="N">Adenosine Monophosphate</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017964" MajorTopicYN="Y">Itraconazole</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020935" MajorTopicYN="Y">MAP Kinase Signaling System</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008545" MajorTopicYN="Y">Melanoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">AMPKα</Keyword>
        <Keyword MajorTopicYN="N">ERK signaling</Keyword>
        <Keyword MajorTopicYN="N">Itraconazole</Keyword>
        <Keyword MajorTopicYN="N">Melanoma</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>30</Day>
          <Hour>20</Hour>
          <Minute>37</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35094205</ArticleId>
        <ArticleId IdType="doi">10.1007/s12013-021-01048-y</ArticleId>
        <ArticleId IdType="pii">10.1007/s12013-021-01048-y</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Cui, S., Wang, J., Wu, Q., Qian, J., Yang, C., &amp; Bo, P. (2017). Genistein inhibits the growth and regulates the migration and invasion abilities of melanoma cells via the FAK/paxillin and MAPK pathways. Oncotarget, 8(13), 21674–21691.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.15535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sundstrøm, T., Espedal, H., Harter, P. N., Fasmer, K. E., Skaftnesmo, K. O., Horn, S., Hodneland, E., Mittelbronn, M., Weide, B., Beschorner, R., Bender, B., Rygh, C. B., Lund-Johansen, M., Bjerkvig, R., &amp; Thorsen, F. (2015). Melanoma brain metastasis is independent of lactate dehydrogenase A expression. Neuro-oncology, 17(10), 1374–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nov040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siegel, R. L., Miller, K. D., &amp; Jemal, A. (2017). Cancer Statistics, 2017. CA: Cancer Journal for Clinicians, 67(1), 7–30.</Citation>
        </Reference>
        <Reference>
          <Citation>Siegel, R. L., Miller, K. D., &amp; Jemal, A. (2015). Cancer statistics, 2015. CA: Cancer Journal for Clinicians, 65(1), 5–29.</Citation>
        </Reference>
        <Reference>
          <Citation>Bränström, R., Chang, Y. M., Kasparian, N., Affleck, P., Tibben, A., Aspinwall, L. G., Azizi, E., Baron-Epel, O., Battistuzzi, L., Bruno, W., Chan, M., Cuellar, F., Debniak, T., Pjanova, D., Ertmański, S., Figl, A., Gonzalez, M., Hayward, N. K., Hocevar, M., Kanetsky, P. A., Leaf, S. L., van Nieuwpoort, F. A., Heisele, O., Palmer, J., Peric, B., Puig, S., Ruffin, A. D., Schadendorf, D., Gruis, N. A., Brandberg, Y., &amp; Newton-Bishop, J. (2010). Melanoma risk factors, perceived threat and intentional tanning: an international online survey. European Journal of Cancer Prevention, 19(3), 216–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CEJ.0b013e3283354847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A., Behjati, S., Biankin, A. V., Bignell, G. R., Bolli, N., Borg, A., Børresen-Dale, A. L., Boyault, S., Burkhardt, B., Butler, A. P., Caldas, C., Davies, H. R., Desmedt, C., Eils, R., Eyfjörd, J. E., Foekens, J. A., Greaves, M., Hosoda, F., Hutter, B., Ilicic, T., Imbeaud, S., Imielinski, M., Jäger, N., Jones, D. T., Jones, D., Knappskog, S., Kool, M., Lakhani, S. R., López-Otín, C., Martin, S., Munshi, N. C., Nakamura, H., Northcott, P. A., Pajic, M., Papaemmanuil, E., Paradiso, A., Pearson, J. V., Puente, X. S., Raine, K., Ramakrishna, M., Richardson, A. L., Richter, J., Rosenstiel, P., Schlesner, M., Schumacher, T. N., Span, P. N., Teague, J. W., Totoki, Y., Tutt, A. N., Valdés-Mas, R., van Buuren, M. M., van ‘t Veer, L., Vincent-Salomon, A., Waddell, N., Yates, L. R., Zucman-Rossi, J., Futreal, P. A., McDermott, U., Lichter, P., Meyerson, M., Grimmond, S. M., Siebert, R., Campo, E., Shibata, T., Pfister, S. M., Campbell, P. J., &amp; Stratton, M. R. (2013). Signatures of mutational processes in human cancer. Nature, 500(7463), 415–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature12477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thompson, J. F., Scolyer, R. A., &amp; Kefford, R. F. (2005). Cutaneous melanoma. Lancet, 365(9460), 687–701.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(05)17951-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hepner, A., Salgues, A., Anjos, C. A. D., Sahade, M., Camargo, V. P., Garicochea, B., Shoushtari, A. N., Postow, M. A., Fernandes, G. S., &amp; Munhoz, R. R. (2017). Treatment of advanced melanoma—A changing landscape. Revista Associacao Medica Brasileira, 63(9), 814–823.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1590/1806-9282.63.09.814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shtivelman, E., Davies, M. Q., Hwu, P., Yang, J., Lotem, M., Oren, M., Flaherty, K. T., &amp; Fisher, D. E. (2014). Pathways and therapeutic targets in melanoma. Oncotarget, 5(7), 1701–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.1892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chien, A. J., Moore, E. C., Lonsdorf, A. S., Kulikauskas, R. M., Rothberg, B. G., Berger, A. J., Major, M. B., Hwang, S. T., Rimm, D. L., &amp; Moon, R. T. (2009). Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proceedings of the National Academy of Sciences of the United States of America, 106(4), 1193–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0811902106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berghoff, A. S., &amp; Preusser, M. (2018). New developments in brain metastases. Therapeutic Advances in Neurological Disorders, 11, 1756286418785502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1756286418785502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hernandez, J. J., Pryszlak, M., Smith, L., Yanchus, C., Kurji, N., Shahani, V. M., &amp; Molinski, S. V. (2017). Giving drugs a second chance: overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics. Frontiers in Oncology, 7, 273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2017.00273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pandya, N. A., Atra, A. A., Riley, U., &amp; Pinkerton, C. R. (2003). Role of itraconazole in haematology/oncology. Archives of Disease in Childhood, 88(3), 258–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/adc.88.3.258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chong, C. R., Xu, J., Lu, J., Bhat, S., Sullivan, Jr, D. J., &amp; Liu, J. O. (2007). Inhibition of angiogenesis by the antifungal drug itraconazole. ACS Chemical Biology, 2(4), 263–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/cb600362d</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim, J., Tang, J. Y., Gong, R., Kim, J., Lee, J. J., Clemons, K. V., Chong, C. R., Chang, K. S., Fereshteh, M., Gardner, D., Reya, T., Liu, J. O., Epstein, E. H., Stevens, D. A., &amp; Beachy, P. A. (2010). Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell, 17(4), 388–99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2010.02.027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim, J., Aftab, B. T., Tang, J. Y., Kim, D., Lee, A. H., Rezaee, M., Kim, J., Chen, B., King, E. M., Borodovsky, A., Riggins, G. J., Epstein, Jr, E. H., Beachy, P. A., &amp; Rudin, C. M. (2013). Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell, 23(1), 23–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2012.11.017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim, D. J., Kim, J., Spaunhurst, K., Montoya, J., Khodosh, R., Chandra, K., Fu, T., Gilliam, A., Molgo, M., Beachy, P. A., &amp; Tang, J. Y. (2014). Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. Journal of Clinical Oncology, 32(8), 745–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2013.49.9525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rudin, C. M., Brahmer, J. R., Juergens, R. A., Hann, C. L., Ettinger, D. S., Sebree, R., Smith, R., Aftab, B. T., Huang, P., &amp; Liu, J. O. (2013). Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer. Journal of Thoracic Oncology, 8(5), 619–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/JTO.0b013e31828c3950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsubamoto, H., Sonoda, T., &amp; Inoue, K. (2014). Impact of itraconazole on the survival of heavily pre-treated patients with triple-negative breast cancer. Anticancer Research, 34(7), 3839–44.</Citation>
        </Reference>
        <Reference>
          <Citation>Inoue, K., Tsubamoto, H., Isono-Nakata, R., Sakata, K., &amp; Nakagomi, N. (2018). Itraconazole treatment of primary malignant melanoma of the vagina evaluated using positron emission tomography and tissue cDNA microarray: a case report. BMC Cancer, 18(1), 630.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-018-4520-5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shackelford, D. B., &amp; Shaw, R. J. (2009). The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nature Reviews Cancer, 9(8), 563–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mihaylova, M. M., &amp; Shaw, R. J. (2011). The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nature Cell Biology, 13(9), 1016–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb2329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faubert, B., Vincent, E. E., Poffenberger, M. C., &amp; Jones, R. G. (2015). The AMP-activated protein kinase (AMPK) and cancer: many faces of a metabolic regulator. Cancer Letters, 356(2 Pt A), 165–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2014.01.018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo, L., Bai, Y., Ji, S., &amp; Ma, H. (2019). MicroRNA‑98 suppresses cell growth and invasion of retinoblastoma via targeting the IGF1R/k‑Ras/Raf/MEK/ERK signaling pathway. International Journal of Oncology, 54(3), 807–820.</Citation>
        </Reference>
        <Reference>
          <Citation>Yu, Z., Ye, S., Hu, G., Lv, M., Tu, Z., Zhou, K., &amp; Li, Q. (2015). The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy. Future Medicinal Chemistry, 7(3), 269–89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4155/fmc.14.143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang, H., Jiang, H., Zhang, H., Liu, J., Hu, X., &amp; Chen, L. (2019). Ribophorin II potentiates P-glycoprotein- and ABCG2-mediated multidrug resistance via activating ERK pathway in gastric cancer. International Journal of Biological Macromolecules, 128, 574–582.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijbiomac.2019.01.195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tandon, M., Chen, Z., Othman, A. H., &amp; Pratap, J. (2016). Role of Runx2 in IGF-1Rβ/Akt- and AMPK/Erk-dependent growth, survival and sensitivity towards metformin in breast cancer bone metastasis. Oncogene, 35(36), 4730–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2015.518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Head, S. A., Shi, W., Zhao, L., Gorshkov, K., Pasunooti, K., Chen, Y., Deng, Z., Li, R. J., Shim, J. S., Tan, W., Hartung, T., Zhang, J., Zhao, Y., Colombini, M., &amp; Liu, J. O. (2015). Antifungal drug itraconazole targets VDAC1 to modulate the AMPK/mTOR signaling axis in endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 112(52), E7276–85.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen, M. B., Liu, Y. Y., Xing, Z. Y., Zhang, Z. Q., Jiang, Q., Lu, P. H., &amp; Cao, C. (2018). Itraconazole-induced inhibition on human esophageal cancer cell growth requires AMPK activation. Molecular Cancer Therapeutics, 17(6), 1229–1239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-17-1094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang, G., Liu, M., Wang, Q., Shen, Y., Mei, H., Li, D., &amp; Liu, W. (2017). Itraconazole exerts its anti-melanoma effect by suppressing Hedgehog, Wnt, and PI3K/mTOR signaling pathways. Oncotarget, 8(17), 28510–28525.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.15324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li, L., Zhao, D., Cheng, G., Li, Q., Chu, Y., Chu, H., Ding, Y., &amp; Li, C. β-elemene suppresses Warburg effect in NCI-H1650 non-small-cell lung cancer cells by regulating the miR-301a-3p/AMPKà axis. Bioscience Reports, 40(6), BSR20194389.</Citation>
        </Reference>
        <Reference>
          <Citation>Peng, Y. G., &amp; Zhang, L. (2019). Wedelolactone suppresses cell proliferation and migration through AKT and AMPK signaling in melanoma. The Journal of Dermatological Treatment, 30(4), 389–395.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/09546634.2018.1527996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen, L., Chen, Q., Deng, G., Kuang, S., Lian, J., Wang, M., &amp; Zhu, H. (2016). AMPK activation by GSK621 inhibits human melanoma cells in vitro and in vivo. Biochemical and Biophysical Research Communications, 480(4), 515–521.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2016.10.040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kfoury, A., Armaro, M., Collodet, C., Sordet-Dessimoz, J., Giner, M. P., Christen, S., Moco, S., Leleu, M., de Leval, L., Koch, U., Trumpp, A., Sakamoto, K., Beermann, F., &amp; Radtke, F. (2018). AMPK promotes survival of c-Myc-positive melanoma cells by suppressing oxidative stress. Embo j, 37, 5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/embj.201797673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maehara, O., Suda, G., Natsuizaka, M., Ohnishi, S., Komatsu, Y., Sato, F., Nakai, M., Sho, T., Morikawa, K., Ogawa, K., Shimazaki, T., Kimura, M., Asano, A., Fujimoto, Y., Ohashi, S., Kagawa, S., Kinugasa, H., Naganuma, S., Whelan, K. A., Nakagawa, H., Nakagawa, K., Takeda, H., &amp; Sakamoto, N. (2017). Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma. Carcinogenesis., 38(11), 1073–1083.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/carcin/bgx095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li, X., Dong, M., Zhou, J., Zhu, D., Zhao, J., &amp; Sheng, W. (2019). C6orf106 accelerates pancreatic cancer cell invasion and proliferation via activating ERK signaling pathway. Molecular and Cellular Biochemistry, 454(1-2), 87–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11010-018-3455-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riverso, M., Montagnani, V., &amp; Stecca, B. (2017). KLF4 is regulated by RAS/RAF/MEK/ERK signaling through E2F1 and promotes melanoma cell growth. Oncogene., 36(23), 3322–3333.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2016.481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ko, G. A., &amp; Cho, S. K. (2018). Phytol suppresses melanogenesis through proteasomal degradation of MITF via the ROS-ERK signaling pathway. Chemico-Biological Interactions, 286, 132–140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cbi.2018.02.033</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
